GREENSBORO, N.C. — Novant Health is now initiating patient enrollment in CytoDyn’s Phase 2 clinical trial for COVID-19 patients with mild to moderate indications.
Novant Health is the first in the in the southeastern U.S. to initiate the Phase 2 trial which is also the second clinical trial site in the nation.
“COVID-19 is the most significant health threat of our generation,” said Dr. Eric Eskioglu, Executive Vice President and Chief Medical Officer for Novant Health. “We want to thank CytoDyn for partnering with us in this very important leronlimab clinical drug trial. With lives at risk, we are working together towards an effective treatment solution.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, added, “We are very pleased to work closely with Novant Health, one of the leading providers of innovative healthcare in the Southeast region of our country. This pandemic is creating an opportunity for all healthcare professionals to collaborate in order to bring a potential therapeutic benefit to so many affected people. Based upon the results we have seen with several New York patients, we are hopeful that leronlimab can provide a benefit to patients throughout the country.”
CytoDyn is also conducting a second COVID-19 trial this week. This trial is a Phase 2b/3 for severely ill COVID-19 patients.
More information provided by CytoDyn.
About Leronlimab (PRO 140)
The FDA has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of GvHD.
About CytoDyn
CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in April of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at www.cytodyn.com.
CORONAVIRUS NEWS
RELATED: Can our pets get COVID-19?
RELATED: City of Burlington amends state of emergency to further stop spread of coronavirus, officials say
FACTS NOT FEAR
Remember facts, not fear when talking about the coronavirus. You should take the same measures recommended by health leaders to prevent the spread of the flu and other viruses. That means washing your hands, avoiding touching your face, and covering coughs and sneezes.
WHERE YOU GET INFORMATION ABOUT THE CORONAVIRUS IS IMPORTANT
It is important to make sure the information you are getting about the coronavirus is coming directly from reliable sources like the CDC and NCDHHS. Be careful not to spread misinformation about coronavirus on social media.
NC CORONAVIRUS HOTLINE
The state also has a special hotline set up where you can call 2-1-1 or 866-462-3821 for more information on the coronavirus. You can also submit questions online at ncpoisoncontrol.org or select chat to talk with someone about the virus.
You can also text keyword VIRUS to WFMY News 2 at 336-379-5775 to find out more information.
Stay connected to local, national and breaking news: Download the new WFMY News 2 app.
►Text the keyword APP to 336-379-5775
►For the latest weather conditions and forecast text the keyword WEATHER to 336-379-5775
►For local news stories right to your phone text the keyword NEWS to 336-379-5775
►Need our Call for Action Team? Text keyword CFA to 336-379-5775
►For traffic alerts text the word TRAFFIC to 336-379-5775